Immune checkpoint inhibitors (ICIs) have revolutionised treatment of advanced non-small cell lung cancer (aNSCLC), but a proportion of patients had no clinical benefit and even experienced detrimental effects. This study aims to characterise patients experiencing hyperprogression (HPD) and early death (ED) by longitudinal liquid biopsy.
Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
Del Bianco, Paola;Boscolo Bragadin, Andrea;Marra, Ludovica;Pasello, Giulia;Fassan, Matteo;Calabrese, Fiorella;Guarneri, Valentina;Conte, Pier Franco;Indraccolo, Stefano;Bonanno, Laura
2022
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionised treatment of advanced non-small cell lung cancer (aNSCLC), but a proportion of patients had no clinical benefit and even experienced detrimental effects. This study aims to characterise patients experiencing hyperprogression (HPD) and early death (ED) by longitudinal liquid biopsy.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
BJC_2022.pdf
accesso aperto
Tipologia:
Published (publisher's version)
Licenza:
Creative commons
Dimensione
638.35 kB
Formato
Adobe PDF
|
638.35 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
